1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023 - Event-Driven Update

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023 - Event-Driven Update

  • May 2015
  • 407 pages
  • ID: 3161484
In this report:
BY 2023, THE TOTAL JAPANESE AD MARKET IS EXPECTED TO RISE TO $##.## BILLION, AT A CAGR OF ##.##% OVER THE ##-YEAR FORECAST PERIOD.
BY 2023, BACE## INHIBITORS, INCLUDING MERCK'S MK-## AND ASTRAZENECA/ELI LILLY'S AZD-##, ARE EXPECTED TO ACHIEVE SALES OF $##.##M AND $##.##M, RESPECTIVELY, ACCOUNTING FOR ##.##% OF THE OVERALL MARKET.

Summary

Table of Contents

Search Inside

PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2023 - Event-Driven Update

Brief

Alzheimer's Disease is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. During the early stages of disease, sleep disturbances and forgetfulness are generally the first presenting symptoms. In the severe stages, patients with AD require permanent observation either by a home care professional or family member. The quickly declining status of patients with AD results in a drastic reduction in quality of life, both for the patients and their caretakers. With quickly accelerating worldwide prevalence, AD has been identified as a main overall health threat by the worldwide medical community. Meaningful efforts have been made to develop a additional treatment for AD, as current pharmacologic management is known to only provide temporary improvement of symptoms. Without therapies that effectively stop or reverse the course of the disease, a important area opportunity exists for the development of an effective pharmacologic approach.

Features

Which of these DMTs will attain high sales revenues during 2013-2023, and in which markets?

- Will amyloid-based therapies face adoption challenges in the sector? What is the projected uptake of additional passive immunotherapies and BACE inhibitors over the forecast period?

- How big an impact will Lundbeck's LuAE-58054 and Forum/Mitsubishi Tanabe's EVP-6124 have on the schizophrenia market? What do leading opinion leaders think of these treatment approaches?

- What are the singular challenges in AD, and how will they affect the growth of the market globally?

Main results

- Symptoms related to AD require superior treatment options.

- Amyloid beta is the focus of the late-stage pipeline.

- Disease-modifying therapies including passive immunotherapies and BACE inhibitors will revitalize the AD market.

Overview

- Overview of AD and mild cognitive impairment, including etiology, general symptoms, country-specific compliance/caregiving data and epidemiology.

- Annualized AD market revenue, annual cost of treatment and usage patterns from 2013 and estimate for ten years to 2023.

- Key topics covered include tactical competitor assessment, unmet needs, clinical trial mapping and implications for the AD market.

- Pipeline analysis: exhaustive data split across AD disease severities for disease-modifying and symptomatic therapies with novel mechanisms of action in AD, including Lilly's solanezumab, Biogen's aducanumab, Roche's gantenerumab and crenezumab. Merck & Co.'s M-8931, and Lilly/AstraZeneca's AZD-3293.

- Analysis of the current and future market competition in the overall AD drug market. Insightful review of the top industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Great reasons to purchasey

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most ambitious pipelines.

- Develop strategic management by understanding the trends shaping and driving the AD market.

- Drive revenues by understanding the main trends, innovative products and technologies, market segments, and firms likely to impact the overall AD market in the outlook.

- Specified effective sales and marketing strategies by understanding the challenging landscape and by analyzing the performance of different competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a ambitious advantage.

- Track drug sales in the overall AD market from 2013-2023.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and tactical partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2018

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2018

  • $ 3500
  • October 2018

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2018 ...

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2018

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Adrenoleukodystrophy (Adrenomyeloneuropathy/ ...

Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2018

Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2018

  • $ 3500
  • September 2018

Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2018SummaryGamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies ...

Psoriasis - Pipeline Review, H2 2018 $ 2500 September 2018


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on